Zydus Lifesciences forms 50:50 JV in Sri Lanka for pharma manufacturing

Marquee Jv AnnouncedStrategic Transactions View source PDF

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.9%1-day move

₹1102.00

prior close

₹1104.70

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.3+0.2-0.0+0.9+0.9+0.6-0.0+3.3+4.0+4.1+4.2———

Up moveDown movePending

AI summary

Zydus Lifesciences has entered a 50:50 joint venture with Sunshine Healthcare Lanka to form Zydus Sunshine Lifesciences (Private) Limited. Zydus will invest up to USD 5 million in one or more tranches; total JV commitment exceeds USD 20 million. The JV will set up a pharmaceutical manufacturing facility on nearly four acres in the Horana Export Processing Zone, Sri Lanka, serving the local retail market. Zydus Sunshine was incorporated on May 30, 2026. Zydus appoints the chairperson with a casting vote; board has 6 directors split equally. Subscription expected within 90 working days. Not a related party transaction.

Likely market impact

Expands Zydus manufacturing footprint into Sri Lanka and reduces import dependence locally. Strategic but small investment relative to company size.